In general, if the atoms that make up the ring contain heteroatoms, such rings become heterocycles, and organic compounds containing heterocycles are called heterocyclic compounds. An article called DNA-repair status should be assessed in treatment-emergent neuroendocrine prostate cancer before platinum-based therapy, published in 2022-03-01, which mentions a compound: 41575-94-4, Name is cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), Molecular C6H12N2O4Pt, HPLC of Formula: 41575-94-4.
Objectives : This study sought to provide contemporary data from a multi-institution with respect to DNA-repair genes (DRGs) status and its impact on effects of platinum-based chemotherapy in treatment-emergent neuroendocrine prostate cancer (t-NEPC), for which little data exist. Patients and Methods : All patients were retrospectively collected with eligible biopsied tissues for targeted next generation sequencing (NGS). The main outcomes were radiol. progression-free survival and overall survival according to Response Evaluation Criteria in Solid Tumors, version 1.1. Results : Among the 43 NEPC patients, 13/43 (30%) harbored homozygous deletions, deleterious mutations, or both in DRGs. Eleven patients (11/13, 85%) with DRGs aberrations had effective response, including 7 patients with BRCA1/2 defects and 2 with mismatch repair-deficient caused by MSH2 alterations. While significantly fewer responders (30%) were detected in patients without DRGs aberrations (odds ratio = 12.83, p = 0.003). Compared with patients without genomic DRGs aberrations, the hazard ratio (HR) for radiol. progression in those with DRGs defects was 0.42 (95% confidence interval [CI]: 0.19-0.93), and the HR for death was 0.65 (95% CI: 0.24-1.72). The most common adverse event of Grade 3 or 4 was anemia, as noted in 7 patients (16%). Conclusion : The DRGs status is therapeutically meaningful in t-NEPC. Given the potential responses to platinum-based chemotherapy, our findings support the clin. use of NGS in t-NEPC patients to identify DRGs aberrations.
If you want to learn more about this compound(cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II))HPLC of Formula: 41575-94-4, you may wish to communicate with the author of the article,or consult the relevant literature related to this compound(41575-94-4).
Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics